Suaya JA, et al. - In this post hoc analysis of the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), researchers evaluated the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ≥65 years with at-risk conditions. Findings demonstrated significant and persistent efficacy of PCV13 against vaccine-serotype community-acquired pneumonia (VT-CAP) in at-risk older adults.